Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02892201 · ClinicalTrials.gov registry record · Phase 2
Pembrolizumab in HNSCC With Residual Disease After Radiation
A Phase 2 study, sponsored by Yale University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 9
- Enrollment target
NCT02892201 is a Phase 2 study that was terminated before completion, run by Yale University. The registered enrollment target is 9 participants.
The verdict
NCT02892201, a Phase 2 study, was terminated before completion, sponsored by Yale University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 9 participants
- Enrollment target
Study Summary
This is a phase II study for patients with squamous cell carcinoma of the head and neck who have residual disease following definitive therapy with radiation (with or without systemic therapy). Patients must be diagnosed with residual disease within 24 weeks of completion of radiation therapy. Residual disease must be biopsy proven before the patient can consent to the trial, and can be either from lymph nodes in the neck, or from the primary tumor site. Prior to beginning study therapy patients are evaluated by an ENT to determine if they have disease amenable to surgical resection. Both resectable and unresectable patients will be eligible for participation in the study.
Interventions
- DRUG Pembrolizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2016-09-08 |
| Est. Completion | 2020-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02892201
The ClinicalTrials.gov registry entry for NCT02892201 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Pembrolizumab is the first listed.
NCT02892201 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02892201 about?
NCT02892201 is a clinical study titled "Pembrolizumab in HNSCC With Residual Disease After Radiation". This is a phase II study for patients with squamous cell carcinoma of the head and neck who have residual disease following definitive therapy with radiation (with or without systemic therapy). Patients must be diagnosed with residual disease within 24 weeks of completion of radiation therapy. Resid...
What is the current status of trial NCT02892201?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 9 participants. The study started on 2016-09-08. Estimated completion is 2020-03.
What interventions are being tested in trial NCT02892201?
The interventions under investigation include: Pembrolizumab (DRUG).
Who is sponsoring clinical trial NCT02892201?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.